Published in Medical Devices and Surgical Technology Week, March 13th, 2005
"Using proteomic analysis," oncologists in Japan "previously identified calreticulin (CRT) as a potentially useful urinary marker for bladder cancer."
In their subsequent study, H. Iwaki and coauthors at the Shiga University of Medical Science "also identified gamma-synuclein (SNCG) and a soluble isoform of catechol-o-methyltransferase (s-COMT) as novel candidates for tumor markers in bladder cancer, by means of proteomic analysis."
"In the process of establishing a superior tumor marker system, we investigated the diagnostic value of a combination assay...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.